Structural requirements for binding to the δ opioid receptor: Alkyl replacements at the third residue of deltorphin I by Heyl, Deborah L. et al.
Letters in Peptide Science, 2 (1995) 277-284 277 
ESCOM 
LIPS 090 
Structural requirements for binding to the opioid receptor: 
Alkyl replacements at the third residue of deltorphin I 
D e b o r a h  L. Heyl  a'*, Hass iba  Bouzi t  a and  Carol  Mous ig ian  b 
aDepartment of Chemistry, Eastern Michigan University, Ypsilanti, MI 48197, US.A. 
hCollege of Pharmacy, The University of Michigan, Ann Arbor, MI 48109, U S. A. 
Received 6 November 1995 
Accepted 27 November 1995 
Keywords." [3-Substitution; Hydrophobicity; Nonpolar; Phenylalanine; Sterie effect 
SUMMARY 
The naturally occurring heptapeptide deltorphin I (Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2) exhibits extremely high 
affinity and selectivity for the ~ opioid receptor. In an ongoing investigation of the features of this compound that 
confer these properties, seven new analogs of the peptide, in which phenylalanine at position three was replaced 
with amino acids containing alkyl side chains, were synthesized and tested for binding to g, 5, and ~ opioid 
receptors. These substitutions, including tert-leucine, tert-butylalanine, c~-aminobutyric acid, norvaline, norleucine, 
[3-cyclopentylalanine and octahydroindole-2-carboxylic acid, assessed the importance of aromaticity and lipophil- 
icity/steric distribution of the side chain at this position in the binding interaction. Findings indicated that: (i) 
aromaticity at position three is not required for binding, and (ii) hydrophobic character, size, steric distribution 
and conformational flexibility influence affinity at the 5 receptor. The data suggest that substitutions at the 
[3-carbon of this residue disrupt the binding conformation of the peptide and possibly provide adverse steric 
effects. 
I N T R O D U C T I O N  
Deltorphins I and II (Tyr-D-Ala-Phe-Asp-Val- 
Val-Gly-NH 2 and Tyr-D-Ala-Phe-Glu-Val-Val- 
Gly-NH2, respectively), isolated from amphibian 
skin, possess some of the highest 5 opioid affin- 
ities and selectivities among all natural and syn- 
thetic compounds known to date [1]. Studies 
suggest that the high selectivity of these hepta- 
peptides is due largely to the anionic side chain of 
the fourth residue, and to its location relative to 
hydrophobic residues in the C-terminal address 
domain [2-4], which are essential for high g-bind- 
ing affinity [5]. On the other hand, the N-terminal 
message domain affects mostly signal transduction 
of biological responses and facilitates receptor 
recognition [6]. This family of 5-selective peptides 
has been under investigation in our laboratory as 
well as others, in order to determine which fea- 
tures are instrumental in inducing high 5-binding 
affinity, and specificity. This information is essen- 
tial for the specific assignment of pharmacological 
*To whom correspondence should be addressed. 
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roles to each of the opioid receptor types (p., 8, 
and ~) and their subtypes. Studying which mol- 
ecular characteristics are important for the activ- 
ity of these inherently selective peptides is there- 
fore a precursor for the development of receptor- 
specific peptidomimetic analgesic drugs that lack 
unwanted side effects. 
Previous studies on opioid peptides such as 
enkephalins have indicated that tyrosine and 
phenylalanine are important in the binding phar- 
macophore, and that ~ and 8 receptors might 
interact differently with each of these amino acid 
residues [7-9]. The topographical relationship of 
the aromatic side chains of these critical residues 
is important in receptor discrimination and bind- 
ing. It has been demonstrated that the side chains 
of certain amino acids in the deltorphin sequence 
are amenable to modification without a substan- 
tial loss of binding affinity [3]. Evidence from 
structure-activity relationship (SAR) studies per- 
formed on linear and conformationally restricted 
opioids in our laboratory, as well as others, sug- 
gests several points, the most important of which 
are: (i) there are possible differences in the binding 
interaction at the phenylalanine residue between 
enkephalins and deltorphins, because the pharma- 
cophoric residues are separated by different linear 
distances in the peptide chain [10-14]; (ii) elec- 
tronic character and lipophilicity are important 
determinants in binding affinity at this residue 
[11-16]; and (iii) the Phe 4 aromatic side chain of 
linear enkephalins is required for binding at the 8 
receptor [17], but aromaticity at the phenylalanine 
residue is not a requirement for 8 binding in some 
opioid peptides, including the deltorphins [11]. In 
addition, conformationally constrained amino 
acids such as 2-aminoindane-2-carboxylic acid 
(Aic) and 2-aminotetralin-2-carboxylic acid (Atc) 
have been substituted at this position, and the 
peptides have maintained opioid binding charac- 
teristics [7,15]. 
We previously reported [11] the substitution of 
Phe 3 of deltorphin I with [3-cyclohexylalanine 
(Cha), which resulted in a compound with high 8- 
binding affinity. Similar 8 affinity was obtained 
when the benzyl moiety of phenylalanine was 
replaced with the nonaromatic branched alkyl 
chain of leucine. 
On the other hand, substitution of phenyl- 
alanine with valine yielded an analog with a pro- 
nounced decrease in 8 affinity. Since steric bulk 
and lipophilicity of the side chain at residue three 
are two important features for high 8-binding 
affinity [11-16], the results obtained for the valine 
analog were attributed to its short side chain. 
However, substitution of phenylalanine with iso- 
leucine resulted in a compound with a much 
lower 8 affinity than that of the Leu 3 analog. 
Given the similarities of the latter three amino 
acid side chains, it was assumed that the presence 
of additional alkyl substituents at the [3-carbon in 
valine and isoleucine might disrupt the proper 
conformation of the molecule or produce steric 
hindrance [11]. 
The need for further examination of these 
effects prompted the synthesis of seven new del- 
torphin analogs in which residue three was re- 
placed by various other aliphatic amino acids with 
varying lipophilicity, molecular volume, and de- 
gree of substitution at the [~-carbon. This study 
was specifically designed to further investigate the 
impact of a lack of aromaticity at the third resi- 
due in deltorphin I, as well as to assess steric 
influences of this residue on 8 receptor binding. 
Although a considerable amount of SAR data 
have been collected on deltorphins, much remains 
to be learned in order to examine the role of the 
and 8 receptors in the production of analgesia. 
METHODS 
Peptide synthesis 
Most of the protected amino acids and coup- 
ling agents were purchased from Bachem Cali- 
fornia, Torrance, CA (including Tle, Abu, Nva 
and Nle) and Bachem Bioscience, King of Prussia, 
PA (including t-BuAla and Cpa, the latter of 
which was obtained in unprotected form and 
reacted with di-t-butyl dicarbonate in a dimethyl- 
formamide/water mixture after treatment with 2 
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equiv of sodium hydroxide). Boc-octahydroindole- 
2-carboxylic acid was purchased from Synthetech, 
Inc., Albany, OR. Solvents and deprotecting a- 
gents were obtained from Fisher Scientific, Itasca, 
IL and from Aldrich Chemical Co., Milwaukee, 
WI. Radioligands were purchased from New Eng- 
land Nuclear, Wilmington, DE, from Multiple Pep- 
tide Systems, San Diego, CA and from Amersham, 
Arlington Heights, IL, and frozen guinea pig 
brains were obtained from Rockland, Inc., Gil- 
bertsville, PA. The peptides were prepared on a 
St. John's Associates (Beltsville, MD) manual sha- 
ker using standard solid phase techniques for N- 
cx-t-butyloxycarbonyl (Boc) protected amino acids 
on p-methylbenzhydrylamine (MBHA) resin (1.1 
mmol/g). The side chains of tyrosine and aspar- 
tate were protected as the 2,6-dichlorocarboben- 
zyloxy and benzyl derivatives, respectively. The 
deprotection solution was 30% trifluoroacetic acid 
(TFA) in dichloromethane (DCM). Dicyclohexyl- 
carbodiimide (DCC) and hydroxybenzotriazole 
(HOBO were used as coupling agents. The proto- 
col for peptide synthesis in each cycle was as 
follows: 
(1) addition of Boc-amino acid in DCM (3 
equiv); 
(2) addition of HOBt (2.4 equiv); 
(3) addition of DCC (2.4 equiv); 
(4) mixing/shaking for 4 h; 
(5) washing with DCM (3 x 2 rain); 
(6) checking for completion of reaction with 
the ninhydrin test [18] and recoupling if necessary; 
(7) Boc deprotection with 30% TFA in DCM 
(30 rain); 
(8) washing with DCM (3 x 2 min); 
(9) neutralization with diisopropylethylamine 
(DIEA) in DCM (10 min); 
(10) washing with DCM (3 x 2 min). 
Simultaneous deprotection and cleavage from 
the resin were accomplished by treatment with 
90% anhydrous HF and 10% anisole scavenger 
(10 ml of HF and 1 ml of anisole per gram of 
resin) at 0 °C for 1 h. After evaporation of the 
HF, the peptide resin was washed with diethyl 
ether and 'the peptide was extracted with 70% 
acetonitrile/30% water (with 0.1% TFA), concen- 
trated under reduced pressure, diluted with water, 
and lyophilized. Crude peptides were purified to 
homogeneity by preparative reversed-phase high 
performance liquid chromatography (RP-HPLC) 
on a Vydac Cl8 column (2.2 x 25.0 cm, 10 ml/min) 
with a linear gradient of water (0.1% TFA) to 
50% acetonitrile (0.1% TFA), followed by lyo- 
philization. 
T A B L E  l 
O P I O I D  R E C E P T O R  B I N D I N G  A F F I N I T I E S  O F  D E L T O R P H I N  A N A L O G S  
Pept ide  C o m p o u n d  no. Binding K i (nM)" Ki(l.t)/Ki(~ ) 
D A M G O  D P D P E  
Y-a-F-D-V-V-G-NH 2 de l to rph in  1 677 + 66.0 1.73 + 0.211 391 
Y-a-(Tle) -D-V-V-G-NH 2 1 >10 000 b 2590 + 207 - 
Y-a- ( t -BuAla) -D-V-V-G-NH 2 2 3040 + 480 56.6 _+ 8.50 53.7 
Y-a- (Abu)-D-V-V-G-NH 2 3 >10 000 ~ 79.1 + 13.8 - 
Y-a- (Nva) -D-V-V-G-NH 2 4 2570 _+ 189 27.5 _+ 3.97 93.5 
Y-a-(NIe)-D-V-V-G-NH 2 5 1020 + 96.1 10.2 + 0.712 100 
Y-a- (Cpa) -D-V-V-G-NH 2 6 4260 + 293 366 _+ 30.4 11.6 
Y-a-(Oic)-D-V-V-G-NH 2 7 >10 000 d 423 + 21.9 - 
D A M G O  = [3H][D-Ala2,NMePhe%GlyS-ol]enkephalin; D P D P E  = [3H][D-Pen2,D-PenS]enkephalin. 
" Average values  were de te rmined  from two to four assays performed in triplicate, +_ s tandard  error  of  the mean;  two assays were 
per formed  to de te rmine  g and  ~: affinity cons tan ts  in excess of  10 gM.  Disp lacement  agains t  the ~: I igand U69,593 was found 
to be less than  7.0% at 10 I.tM for all  analogs.  
b 32.0% d i sp lacement  at  10 laM. 
c 23.7% d i sp lacement  at  10 laM. 
J 26.0% d i sp lacement  at 10 ~tM. 
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Fig. 1. Structures of the amino acids in the third position of compounds 1-7. 
Peptide analysis 
Peptide purity was assessed by analytical RP- 
HPLC. Peaks were monitored at 230 and 280 nm. 
All compounds were at least 95% pure as ana- 
lyzed by. peak integration. Proton nuclear magnet- 
ic resonance (1H NMR) spectra were obtained on 
a Bruker spectrometer at 250 MHz. Samples 
(approx. 1 mg) were dissolved in DMSO. Diag- 
nostic resonances and peak patterns confirmed 
the presence of all indicated residues. Electrospray 
mass spectrometry confirmed the appropriate 
molecular weights. 
Opioid receptor binding assays 
Receptor binding assays measured displacement 
by the test compounds of radiolabelled receptor- 
selective ligands from guinea pig brain homo- 
genates, using 1.2 nM [3H]DAMGO for the Ix 
receptor, 2.5 nM [3H]DPDPE for the 8 receptor 
and 1.0 nM [3H]U69,593 for the ~c receptor. This 
protocol has been described previously [13]. ICs0 
values were obtained by linear regression from 
plots relating inhibition of specific binding to the 
logarithm of 12 different ligand concentrations, 
using the RADLIG computer software (Biosoft 
Software, Cambridge, UK) [19]. For binding to ~c 
receptors, which was expected to be weak, the 
protocol was altered to include only five ligand 
concentrations and was performed in duplicate. 
K i values were calculated using values for K D of 
each ligand. Saturation binding experiments deter- 
mined the K D range of each ligand as follows: 
[3H]DAMGO = 1.31-3.60 nM; [3H]DPDPE = 
1.60-1.72 nM; and [3H]U69,593 = 1.13-1.40 nM. 
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K~ values reported represent the mean of two to 
four determinations, each performed in triplicate. 
RESULTS 
All newly synthesized deltorphin analogs were 
assayed for binding affinity to opioid receptors. 
The amino acids substituted at position three are 
depicted in Fig. 1, and Table 1 summarizes the 
binding affinity data obtained. For comparison, 
Table 1 also lists the opioid binding affinities of  
deltorphin I. Binding to ~c receptors was negligible 
for all compounds. While binding affinities for bt 
receptors were assessed, none of the analogs dis- 
played significant affinity for this receptor (in- 
cluding the lead compound,  deltorphin I). There- 
fore, no consistent observation can be made a- 
bout the binding pocket of  the bt receptor, and 
the following discussion will focus on effects at 
the 5 receptor. Physicochemical data for all newly 
reported analogs are provided in Table 2. The 
relative R P - H P L C  elution times of the analogs 
provide a good measure of  their relative lipophil- 
icities, commensurate with other utilized scales of 
hydrophobicity [20]. 
For the peptide containing tert-leucine (Tie), 
analog 1, 5 binding was effectively reduced 1500- 
fold (Ki=2590 nM). In fact, this modification 
proved to be the poorest for 5-receptor binding of 
all those reported here. In compound 2, substitu- 
tion of phenylalanine with tert-butylalanine (t- 
BuAla) resulted in a markedly stronger binding 
affinity (Ki = 56.6 nM) than that of  the Tle ana- 
log, though it was still reduced relative to that of  
deltorphin I. 
In the next group of analogs (3-5), nonbranched 
alkyl side chains of varying length replaced the 
benzyl moiety of the native Phe 3. Analog 3 con- 
sisted of a substitution with o~-aminobutyric acid 
(Abu), which gave rise to a reduction in 5-binding 
affinity (K~=79.1 nM). This was not unantici- 
pated, given the small ethyl side chain of  Abu. 
However, this compound retained good 5 selectiv- 
ity, largely due to a drastic reduction in }.t recep- 
tor affinity. Norvaline (Nva) proved to be an 
adequate substitution for phenylalanine in analog 
4; the 5-binding affinity (K~=27.5 nM) was al- 
most threefold better than that of the Abu analog 
as a result of  lengthening the side chain by one 
methylene unit. The binding affinity for the 
receptor, relative to compound 3, improved slight- 
ly as well. In compound 5, substitution with nor- 
leucine (Nle) resulted in a threefold enhancement 
in both bt- and 8-binding affinity relative to com- 
pound 4. Interestingly, compound 5 (K~= 10.2 
nM) displayed affinity for the 8 receptor site 
TABLE 2 
PHYSICOCHEMICAL DATA FOR DELTORPHIN I ANALOGS 
Peptide Compound no. HPLC 
I" I I b 
Purity MS 
(%)~ mol wt d 
Y-a-(TIe)-D-V-V-G-NH 2 1 1.94 43.1 97.2 734.0 
Y-a-(t-BuAla)-D-V-V-G-NH 2 2 5.83 47.2 98.5 749.0 
Y-a-(Abu)-D-V-V-G-NH: 3 0.45 38.8 96.0 706.5 
Y-a-(Nva)-D-V-V-G-NH 2 4 1.25 42.7 98.4 720.5 
Y-a-(NIe)-D-V-V-G-NH 2 5 2.59 46.9 99.8 735.0 
Y-a-(Cpa)-D-V-V-G-NH 2 6 2.52 43.4 95.0 760.5 
Y-a-(Oic)-D-V-V-G-NH 2 7 4.26 45.2 95.0 772.5 
" HPLC K' on a Vydac 218TP CIR column (0.46 cmx25 cm); isocratic conditions at 25% organic component; flow rate of 1 
ml/min. The solvent system was 0.1% TFA in water, 0.1% TFA in acetonitrile. Solvent front breakthrough at 3.4 min. 
b HPLC retention time in rain on a Vydac 218TP C18 column (0.46 cm×25 cm); gradient of 0-50% organic component in 50 min; 
flow rate of 1 ml/min. The solvent system was 0.1% TFA in water, 0.1% TFA in acetonitrile. Solvent front breakthrough at 3.5 
rain. 
c Purity of final product peptide as assessed by RP-HPLC peak integration at 214 or 230 nm (whichever is lower). 
J Molecular weight obtained by electrospray mass spectrometry. 
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within an order of magnitude of the native parent 
peptide, even though the side chain of residue 
three consisted of an n-butyl group rather than an 
aromatic benzyl moiety. Both compounds 4 and 
5 were approximately 100-fold selective for the 8 
receptor over the tx receptor. 
[3-Cyclopentylalanine (Cpa) was substituted for 
Phe 3 due to its lipophilic and nonaromatic, but 
relatively planar, nature. The 8 affinity of com- 
pound 6 (Ki= 366 nM) was much weaker than 
that of deltorphin I. Although g binding also was 
quite poor, this analog suffered a great loss in 8 
selectivity, with a g to 8 K~ ratio of only 12. Ana- 
log 7, containing octahydroindole-2-carboxylic 
acid (Oic), displayed similarly low affinity for the 
8 opioid receptor (K~ =423 nM), despite its lipo- 
philicity. Binding to the g receptor was negligible 
as well. 
DISCUSSION 
The poor 8-binding affinity of analog 1 con- 
firms our earlier suggestion that [3-substitution on 
the side chain of residue three adversely influences 
8 receptor interaction [11]. The side chain of Tle 
is lipophilic, has the same number of carbons as 
that of leucine, and is the same length as that of 
valine, but it is further substituted at the [3-car- 
bon. This must be an unfavorable condition, since 
the 8-binding affinity suffers 200-fold relative to 
that of the leucine analog (Ki= 12.4 nM) and 16- 
fold relative to that of the valine analog (Ki= 160 
nM). It should be noted that a progressive de- 
crease in 8 affinity was observed for analogs 
containing Leu (Ki= 12.4 nM) [11], Ile (I~=94.7 
nM) [11], and Tie (Ki=2590 nM), which have 
respectively one, two and three additional alkyl 
substituents at their [3-carbons. The data pre- 
sented here suggest that the steric and/or confor- 
mational effect triggered by substitution at the [3- 
carbon is the primary factor in determining rela- 
tive binding affinity for the 8 receptor within this 
group of analogs. 
In contrast, the t-BuAla analog, 2, lacks steric 
hindrance around its 13-carbon, which might per- 
mit the molecule to fold into a more favorable 
binding conformation for interaction at the 8 
receptor site. The side chain length of t-BuAla 
parallels that of leucine, 'so it is somewhat surpris- 
ing that the 8 affinity of compound 2 is slightly 
less than that of the previously reported Leu 3 
analog [11]. Still, it should be noted that the 
affinities are within an order of magnitude. It is 
also possible that the ? t-butyl group is too large 
to fit the binding site optimally or contributes to 
an adverse steric effect on conformation. 
One factor that is influenced by the degree of 
[3-substitution is planarity of the side chain. It ap- 
pears that the 8 binding pocket may be narrow and 
selective with regard to where steric bulk is toler- 
ated, easily allowing binding of the fiat phenyl- 
alanine aromatic ring. Each subsequent addition 
of a [3-substituent in our analogs progressively 
interferes with the ability of the side chain to 
adopt a 'flat' conformation, with the third sub- 
stituent (as in a t-butyl group) absolutely forcing 
the groups out of plane. This effect may be due to 
the influence on overall peptide topology as well 
as obstructing a 'fit' of the side chain into the 
binding pocket. The effect of a t-butyl group on 
peptide binding appears more drastic when it is 
substituted closer to the backbone (analog 1); 
substitution at the ? carbon in analog 2 is not 
nearly as detrimental. While both analogs contain 
similarly bulky side chains, the latter analog 
might be expected to have greater local conforma- 
tional flexibility at the third residue. Indeed, it has 
been noted that rotational freedom of this side 
chain is an important element in the 8 binding 
interaction. Restriction of the phenylalanine side 
chain via formation of a double bond between the 
c~ and ~ carbons decreased 8 binding 14-fold, 
while enhancing I1 affinity [15]. In addition, nu- 
clear Overhauser spectroscopy studies have re- 
vealed a proximity between the methyl group of 
D-AIa 2 and the side chain of residue three [21,22], 
and it has been suggested that a steric interaction 
between these groups might change the conforma- 
tion of the [3-turn at the N-terminus of the pep- 
tide [15]. Furthermore, molecular modeling stud- 
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ies of deltorphin analogs have shown potential 
intramolecular interactions between Phe 3 and both 
the Tyr j phenolic ring and the Asp 4 side chain 
[15]. The steric distribution of the side chain of 
residue three therefore may be an important de- 
terminant in maintaining the appropriate binding 
conformation. 
The binding profiles of analogs 3-5 also tend 
to support the assumption that substitution at the 
13-carbon disrupts the proper orientation of the 
molecule for binding to 8 receptors. In these 
compounds, the importance of side chain length 
was explored. Apparently, a long unsubstituted 
alkyl chain at position three can function as an 
integral component in the binding interaction, 
most likely through hydrophobic forces. In addi- 
tion, the optimal spatial orientation of other 
pharmacophoric elements required for binding to 
the 8 receptor site is preserved. While compound 
3 does not bind particularly well, its side chain is 
rather short and the least lipophilic of the group. 
As the length of the alkyl chain is extended in 4 
and 5, binding to the 8 receptor improves signifi- 
cantly, with the affinity of analog 5 being com- 
parable to that of deltorphin I itself. This most 
likely occurs because the side chain of norleucine 
is long enough to reach the binding site of the 8 
receptor and should be able to interact through 
hydrophobic interactions with the 8 receptor site 
in a similar manner to that of the phenylalanine 
side chain. In addition, the [3-carbon is unsub- 
stituted, resulting in the highest 8 affinity of all 
analogs reported here. The 8 opioid affinity of 
analog 5 also is commensurate with that of 
[Leu3]deltorphin I (K~-- 12.4 nM) [11]; this is logi- 
cal given the similar structural characteristics of 
Leu and Nle. 
There is a remarkable contrast (40-fold differ- 
ence) between the k-binding affinities of analogs 
containing ]3-cyclohexylalanine (K~ = 10.5 nM) [11] 
and [3-cyclopentylalanine (analog 6) at position 
three. Apparently, the van der Waals space oc- 
cupied by a flexible cyclohexyl group in the chair 
conformation more closely approximates that of 
the phenylalanine phenyl ring than does that of a 
cyclopentyl group, regardless of the relative plan- 
arity of the latter. While bulky and lipophilic, the 
side chain of ~-cyclopentylalanine is relatively 
rigid, as the carbons in the five-membered ring 
possess little flexibility. This may prevent the 
appropriate arrangement of atoms for interaction 
at the receptor binding pocket. However, it is 
interesting to note that the aromatic five-mem- 
bered ring of [3-thienylalanine is well accommo- 
dated at this position [16]. 
Oic is structurally similar to ~-cyclohexyl- 
alanine, but is more constrained. The decrease in 
conformational mobility of the side chain of ana- 
log 7 apparently prevents ideal interaction with 
the 8 receptor site, since its affinity is 1/40 that of 
[Cha3]deltorphin I [11]. Also, this substitution 
may adversely influence local backbone angles by 
virtue of cyclization via the c~-nitrogen. Substitu- 
tion of bicyclic aromatic systems for the benzyl 
moiety of phenylalanine has been shown to be 
well tolerated in general [15]. However, replace- 
ment of Phe 3 by 1,2,3,4-tetrahydroisoquinoline-3- 
carboxylic acid (Tic) resulted in a substantial loss 
in 8 affinity [15], confirming similar effects on 
other opioid peptides [7,23]. This was at least 
partially attributed to the cyclization via the 
amide nitrogen, since N-methylphenylalanine also 
is a deleterious substitution in position three [15]. 
Oic shares this unfavorable structural feature, 
which probably contributes to its poor binding 
profile. 
CONCLUSIONS 
Although none of the analogs examined in this 
study bound as well or were as 8-selective as the 
parent deltorphin I, our results provide further 
evidence that aromaticity at position three, while 
preferred, clearly is not a requirement for interac- 
tion with the 8 receptor. In addition, the side 
chain must be lipophilic, sufficiently long/flexible 
to reach the binding pocket (possibly interacting 
with the receptor by van der Waals interactions 
or hydrophobic forces), and have minimal [g-sub- 
stitution. The high 8-binding affinity and selectiv- 
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ity of compound 5 (containing Nle) is remarkable 
for an opioid peptide that lacks an aromatic side 
chain at the third residue. 
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